Statins alone are a &gt;$10b annual market, down from $20b annually before Lipitor&#x27;s patent expired.  Pharma companies have proven that curative treatments can be priced near the net present value of all future disease management costs, making cures the most lucrative area of pharma (a good thing if it leads to more of them).  There are billions of private dollars being sunk into heart disease annually.  I&#x27;m not sure exactly what Google is after here but $50m is not going to move the needle from a funding or incentive perspective.